|
typ |
publikacja |
| 3 |
Czasopismo |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 12 |
Czasopismo |
Owens LC, Fleming RA, Restino MS, Cruz JM, Hurd DD.
Stability of amphotericin B 0.05 and 0.5 mg/ml in 20% fat emulsion.
Am J Health-Syst Pharm 1997 ; 54: 683-686. |
| 36 |
Czasopismo |
Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC.
Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods.
Am J Health-Syst Pharm 1995 ; 52: 2423-2426. |
| 59 |
Czasopismo |
Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
| 73 |
Czasopismo |
Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159. |
| 81 |
Czasopismo |
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678. |
| 84 |
Czasopismo |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 99 |
Czasopismo |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 169 |
Czasopismo |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 182 |
Czasopismo |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 198 |
Czasopismo |
Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520. |
| 201 |
Czasopismo |
Thompson DF, Allen LV, Stiles ML.
Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2530-2531. |
| 215 |
Czasopismo |
Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M.
Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs.
Ann Pharmacotherapy 1993 ; 27: 422-426. |
| 244 |
Czasopismo |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 248 |
Czasopismo |
Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304. |
| 249 |
Czasopismo |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 251 |
Czasopismo |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 253 |
Czasopismo |
Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528. |
| 256 |
Czasopismo |
Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA.
Stability of fluconazole in commonly used intravenous antibiotic solutions.
Am J Hosp Pharm 1993 ; 50: 1206-1208. |
| 265 |
Czasopismo |
Trissel LA.
Amphotericin B does not mix with fat emulsion.
Am J Health-Syst Pharm 1995 ; 52: 1463-1464. |
| 266 |
Czasopismo |
Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855. |
| 270 |
Czasopismo |
Heide PE.
Precipitation of amphotericin B from IV fat emulsion.
Am J Health-Syst Pharm 1997 ; 54: 1449. |
| 280 |
Czasopismo |
Allen LV, Stiles ML, Prince SJ, Sylvestri MF.
Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 2427-2433. |
| 283 |
Czasopismo |
Lee MD, Hess MM, Boucher BA, Apple AM.
Stability of amphotericin B in 5% dextrose injection stored at 4 or 25°C for 120 hours.
Am J Hosp Pharm 1994 ; 51: 394-396. |
| 285 |
Czasopismo |
Elmore RL, Contois ME, Kelly J, Noe A, Poirier A.
Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs.
Clin Ther 1996 ; 18: 246-255. |
| 299 |
Czasopismo |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
| 300 |
Czasopismo |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 301 |
Czasopismo |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 307 |
Czasopismo |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 334 |
Czasopismo |
Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992. |
| 335 |
Czasopismo |
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406. |
| 337 |
Czasopismo |
Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533. |
| 435 |
Czasopismo |
Wiest DB, Maish WA, Garner SS, El-Chaar GM.
Stability of amphotericin B in four concentrations of dextrose injection.
Am J Hosp Pharm 1991 ; 48: 2430-2433. |
| 436 |
Czasopismo |
Mitrano FP, Outman WR, Baptista RJ, Palombo JD.
Chemical and visual stability of amphotericin B in 5% dextrose injection stored at 4°C for 35 days.
Am J Hosp Pharm 1991 ; 48: 2635-2637. |
| 439 |
Czasopismo |
Kintzel PE, Kennedy PE.
Stability of amphotericin B in 5% dextrose injection at concentrations used for administration through a central venous line.
Am J Hosp Pharm 1991 ; 48: 283-285. |
| 479 |
Czasopismo |
Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966. |
| 492 |
Czasopismo |
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 496 |
Czasopismo |
Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746. |
| 497 |
Czasopismo |
Kintzel PE, Kennedy PE.
Stability of amphotericin B in 5% dextrose injection at 25°C.
Am J Hosp Pharm 1991 ; 48: 1681. |
| 604 |
Laboratorium |
Stabilité des médicaments dans l'Intermate® SV50, 100, 200
Baxter 1998 |
| 682 |
Czasopismo |
Raymond GG, Davis RL.
Physical compatibility and chemical stability of amphotericin B in combination with magnesium sulfate in 5% dextrose injection.
Ann Pharmacotherapy 1991 ; 25: 123-126. |
| 793 |
Czasopismo |
Ranch?re JY, Latour JF, Fuhrmann C, Lagallarde C, Loreuil F.
Amphotericin B intralipid formulation: stability and particule size.
J Antimicrob Chemother 1996 ; 37: 1165-1169. |
| 892 |
Czasopismo |
Kintzel PE, Smith GH.
Practical guidelines for preparing and administering amphotericin B.
Am J Hosp Pharm 1992 ; 49: 1156-1164. |
| 905 |
Czasopismo |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 984 |
Czasopismo |
Ericsson O, Hallmen AC, Wikstrom I.
Amphotericin B is incompatible with lipid emulsions.
Ann Pharmacotherapy 1996 ; 30: 298. |
| 1057 |
Czasopismo |
Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207. |
| 1135 |
Czasopismo |
Baltz JK, Kennedy P, Minor JR, Gallelli J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1990 ; 47: 2075-2077. |
| 1172 |
Czasopismo |
Jurgens RW, DeLuca PP, Papadimitriou D.
Compatibility of amphotericin B with certain large-volume parenterals.
Am J Hosp Pharm 1981 ; 38: 377-378. |
| 1201 |
Czasopismo |
Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG.
Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures.
Am J Hosp Pharm 1981 ; 38: 1919-1922. |
| 1410 |
Czasopismo |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1415 |
Czasopismo |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74. |
| 1423 |
Czasopismo |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1498 |
Czasopismo |
Cleary JD.
Amphotericin B formulated in a lipid emulsion.
Ann Pharmacotherapy 1996 ; 30: 409-412. |
| 1611 |
Czasopismo |
Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506. |
| 1625 |
Czasopismo |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1703 |
Czasopismo |
Schuster F, Bernard R.
Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln.
Krankenhauspharmazie 1995 ; 16: 101-103. |
| 1712 |
Czasopismo |
Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233. |
| 1713 |
Czasopismo |
Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315. |
| 1721 |
Czasopismo |
Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72. |
| 1754 |
Czasopismo |
Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244. |
| 1803 |
Czasopismo |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1907 |
Czasopismo |
Burger DE, Caldwell JW.
Sustaining treatment of coccidioidal meningitidis by extending the stability of amphotericin B.
Hosp Pharm 2004 ; 39: 554-557. |
| 1925 |
Czasopismo |
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1953 |
Czasopismo |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 1982 |
Czasopismo |
Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837. |
| 2043 |
Czasopismo |
Walker S, Tailor SAA, Lee M, Louie L, Louie M, Simor AE.
Amphotericin B in lipid emulsion : stability, compatibility, and in vitro antifungal activity.
Antimicrob Agents Chemother 1998 ; 42: 762-766. |
| 2090 |
Czasopismo |
Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196. |
| 2247 |
Czasopismo |
Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278. |
| 2262 |
Czasopismo |
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265. |
| 2269 |
Czasopismo |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 3152 |
Czasopismo |
Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644. |
| 3216 |
Czasopismo |
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18 |
| 3249 |
Czasopismo |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3254 |
Czasopismo |
Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270. |
| 3332 |
Laboratorium |
Tigecycline (Tigacyl®) - Summary of Product characteristics
Pfizer 2012 |
| 3408 |
Czasopismo |
Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21. |
| 3539 |
Laboratorium |
Bivalirudin (Angiox®) - Summary of Product Characteristics.
The Medecines Company 2013 |
| 3549 |
Laboratorium |
Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012 |
| 3560 |
Laboratorium |
Linezolid (Zyvox®) - Summary of Product Characteristics
Pharmacia 2013 |
| 3564 |
Laboratorium |
Rocuronium B Braun - Résumé des caractéristiques du produit.
B Braun 2012 |
| 3585 |
Laboratorium |
Benzylpenicillin sodium - Summary of Product Characteristics
Genus Pharmaceuticals 2008 |
| 3591 |
Laboratorium |
Amphotericine B (Fungizone®) - Résumé des caractéristiques du produit
Bristol Myers Squibb 2011 |
| 3638 |
Laboratorium |
Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics
Hospira 2010 |
| 3644 |
Laboratorium |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3662 |
Laboratorium |
Foscavir (Foscarnet®) - Summary of Product Characteristics
Clinigen 2014 |
| 3766 |
Czasopismo |
Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165. |
| 3767 |
Czasopismo |
Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172. |
| 3791 |
plakat |
Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Apifh Congress, Paris November 2014 2014 |
| 3828 |
plakat |
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015 |
| 3829 |
plakat |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015 |
| 3869 |
Czasopismo |
Sun P, Chen J, Zhang Z, Gao X, Chen P, Li X.
Influence of 5% dextrose volume on amphotericin B deoxycholate preparation
J Pharm Pharmacol 2016 ; 68: 433-438. |
| 3871 |
plakat |
Soussi M.A, Soualah-alila R, jenene F, Lazreg O, Razgallah Khrouf M.
Peut-on administrer le céfotaxime en Y avec d'autres médicaments injectables ?
Synprefh Congress Clermont Ferrand, France 2016 |
| 3883 |
Laboratorium |
Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016 |
| 3968 |
Laboratorium |
Ringer lactate - Résumé des Caractéristiques du Produit
Fresenius Kabi 2015 |
| 4055 |
Czasopismo |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4145 |
Czasopismo |
Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
| 4528 |
Czasopismo |
Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61 |
| 4543 |
Czasopismo |
Senarathna G, Strunk T, Petrovski M, Batty K.
Physical compatibility of pentoxifylline and intravenous medications.
Archives of Disease in Childhood 2018 ;104:292–295. |
| 4650 |
Laboratorium |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021 |
| 4837 |
Czasopismo |
De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T.
Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings.
Eur J Clin Pharmacol 2024 ; 80:1079–1087. |
| 4867 |
plakat |
Dazan D, Aït Taleb S, Laroyenne N, Hamam Y, Conreur L, Paoli-Lombardo R, Primas N, Lamy E, Castera-Ducros C, Curti C et al.
Etude des compatibilités entre la nalbuphine et d'autres principes actifs pour optimiser leur administration en service de pédiatrie.
CSH (SNPHPU) Congress sept 2024 2024 |
